Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 14/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15915643 | 0.83 | PARP14 (0.48) | CYP3A4CYP2C9CYP2C19PSIP1PARP14 | |
| SCHEMBL17557850 | 0.83 | BRAF (0.43) | CYP3A4CYP2C9CYP2C19PSIP1BRAF | |
| SCHEMBL1494488 | 0.82 | PTGS1 (0.45) | CYP3A4CYP2C9CYP2C19PSIP1BRAF | |
| SCHEMBL6524486 | 0.81 | BRAF (0.45) | CYP3A4CYP2C9CYP2C19PSIP1BRAF | |
| SCHEMBL1462060 | 0.81 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2C19PSIP1BRAF | |
| SCHEMBL26386321 | 0.81 | CYP2C9 (0.55) | CYP3A4CYP2C9CYP2C19PSIP1BRAF | |
| SCHEMBL25110363 | 0.79 | CYP2C9 (0.52) | CYP3A4CYP2C9CYP2C19PSIP1BRAF | |
| SCHEMBL285333 | 0.79 | CYP3A4 (0.63) | CYP3A4CYP2C9CYP2C19PSIP1BRAF | |
| SCHEMBL856066 | 0.79 | CYP2C9 (0.52) | CYP3A4CYP2C9CYP2C19PSIP1BRAF | |
| SCHEMBL22831995 | 0.78 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19BRAFBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026073-B | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-111247152-B | Cyclic iminopyrimidine derivatives as kinase inhibitors | 璧辰医药技术股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11932647-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3684772-B1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORP (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220251089-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORPORATION (CA) | 2022-08-11 | — | — | US | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-8859548-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| CN-102596937-A | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG | 2012-07-18 | — | — | CN | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | CYP3A4 1823/4885CYP2C9 1687/4885CYP2C19 1448/4885 |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | CYP3A4 3580/4885CYP2C9 3037/4885CYP2C19 2839/4885 |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | CYP3A4 1823/4885CYP2C9 1687/4885CYP2C19 1448/4885 |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | CYP3A4 1823/4885CYP2C9 1687/4885CYP2C19 1448/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | CYP3A4 3580/4885CYP2C9 3037/4885CYP2C19 2839/4885 |
| US-20220251089-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | BRAF, CDK4, RAF1 | CYP3A4 4762/4885CYP2C9 4615/4885CYP2C19 3982/4885 |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | CYP3A4 3580/4885CYP2C9 3037/4885CYP2C19 2839/4885 |
| US-11932647-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | BRAF, CDK4, RAF1 | CYP3A4 4762/4885CYP2C9 4615/4885CYP2C19 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.